Sight Sciences (SGHT) Q2 2026 earnings review
TearCare Reimbursement Ignites Growth, Guidance Raised Again
Sight Sciences delivered a breakout quarter in 26Q2, marking an accelerating revenue growth trajectory (20% YoY to $23.4M). The core story is the explosive 704% surge in Interventional Dry Eye (TearCare) sales following expanded Medicare and commercial reimbursement coverage. With the Interventional Glaucoma (OMNI) segment continuing a steady, stable recovery (+8% YoY), management confidently raised FY26 revenue guidance to $88-92M while simultaneously lowering adjusted OpEx guidance. Cash burn is dropping rapidly, placing the company on a highly credible path to cash flow breakeven without the need for dilutive equity capital.
🐂 Bull Case
Interventional Dry Eye revenue nearly doubled sequentially for the second consecutive quarter to a record $2.7M. Securing reimbursement coverage for CPT code 0563T is effectively transforming the addressable market from cash-pay to standard-of-care.
The company increased revenue by 20% while cutting adjusted operating expenses by 8% YoY. This powerful operating leverage reduced the net loss by 63% to $4.4M, validating the structural path to profitability.
🐻 Bear Case
While IG grew 8% to $20.7M, the standalone glaucoma market remains highly competitive. Growth relies on successfully changing physician workflows to treat pseudophakic patients, which involves heavy commercial lifting.
TearCare's massive growth currently relies heavily on two regional Medicare Administrative Contractors (MACs) and a recent Aetna win. Any delay in winning over the remaining MACs could create a growth plateau in late 2026/2027.
⚖️ Verdict: 🟢
Bullish. The thesis of pivoting TearCare to a reimbursed model is working perfectly. Consecutive guidance raises coupled with declining operating expenses represents the exact combination of growth and discipline that investors reward.
Key Themes
Interventional Dry Eye (TearCare) Explosion
TearCare is accelerating at a remarkable pace. IDE revenue hit $2.7M, up 704% YoY and 98% sequentially. The company successfully added 4.1 million patient lives in Q2, boosting the total covered population to 14.5 million. The alignment of commercial fee schedules with Medicare pricing for CPT code 0563T has catalyzed explosive utilization, proving that reimbursement was the primary bottleneck for widespread adoption.
Interventional Glaucoma (OMNI) Commercial Execution
The core IG business posted its fourth consecutive quarter of stable YoY growth (+8% to $20.7M). A major catalyst was secured in July with Aetna expanding coverage for implant-free glaucoma procedures (OMNI and SION) to 25 million commercial lives, specifically for mild-to-moderate open-angle glaucoma. This removes friction for younger, commercially insured patients.
OMNI Ultra FDA Clearance
The company secured FDA 510(k) clearance for the next-generation OMNI Ultra Surgical System with TruSync Plus technology. This product innovation is designed to improve procedural control and efficiency for surgeons, helping to protect market share against competing MIGS devices and driving potential pricing power in late 2026 and beyond.
Headline Gross Margin Inflated by Tariff Refunds
Management touted a phenomenal 91% gross margin for Q2, but the underlying data contradicts this headline enthusiasm. The result included a $1.4M one-time benefit from macro tariff refunds. Excluding this refund, the base gross margin was 86%—which is flat compared to the prior year. While an 86% margin is still excellent, investors should not expect a sustainable 90%+ margin moving forward.
Litigation Costs Disguising Underlying Cash Flow
Reported cash usage for Q2 was $5.2M, which feels elevated given the $4.4M net loss and claims of OpEx reductions. This included a substantial $5.4M 'litigation success fee' payout tied to the Alcon patent lawsuit. While the company won a $55M judgment in Q1, that cash is tied up in appeals, meaning Sight Sciences is currently suffering negative cash outflows to secure a payout that may not materialize for years.
TearCare Geographic and Payer Concentration
Despite the impressive growth numbers, TearCare's success remains highly concentrated. The vast majority of momentum stems from the First Coast and Novitas MAC jurisdictions. Management must prove they can scale the high-touch, in-person commercial workflow into new, untested geographies as they secure additional MAC coverage. A failure to expand this footprint limits the long-term TAM.
Other KPIs
Decreased 8% YoY from $24.4 million, reflecting the annualized benefits of a prior-year reduction in force. Selling, general, and administrative expenses dropped 5%, showcasing significant leverage as revenue concurrently grew 20%.
Cash balance declined by $5.2M sequentially, but adjusting for the $5.4M legal payout and $1.6M tariff refund, normalized cash burn was just $1.4M (an 81% YoY improvement). The balance sheet remains highly resilient against the $40.0M long-term debt facility.
Guidance
Accelerating. The midpoint of $90 million implies 14% to 19% YoY growth over FY25's $77.4M. This is the second consecutive quarter management has raised this guide (initially $82-88M in Q4, then $83-89M in Q1), driven by massive IDE outperformance.
Accelerating. Raised significantly from the previous $6 - $8 million range. With $4.1M already generated in H1 2026, the guidance implies a continued run-rate of ~$3M per quarter in H2, representing sustained hyper-growth relative to the $1.6M total generated in FY25.
Stable. Raised slightly from the previous $77 - $81 million range, representing 4% to 7% YoY growth. The tightened range signals high visibility into the second half of the year as the OMNI Ultra launch phases in.
Decelerating. Management lowered the expected OpEx envelope from a previous $93 - $96 million range. Generating higher revenue on lower expected spend emphatically secures the pathway to near-term cash flow breakeven.
Key Questions
Alcon Litigation Timeline
With the $5.4M success fee now paid out, are there any further milestone legal payments expected before the Alcon appeal process concludes, and what is the realistic timeframe for final resolution on the $55M payout?
TearCare Account Penetration vs Onboarding
The jump to $2.7M in IDE revenue was impressive. Can you decompose how much of this Q2 growth was driven by increasing utilization within existing First Coast/Novitas accounts versus onboarding entirely new clinical practices?
OMNI Ultra Commercial Strategy
With the 510(k) clearance in hand for OMNI Ultra, what is the planned rollout cadence, and is there an expectation for an ASP uplift relative to the OMNI Edge platform as we move into 2027?
Sustainable Margin Profile
Excluding the highly favorable tariff refund, the underlying IG gross margin remained at 86%. Once your non-China manufacturing facilities are fully scaled, what is the long-term ceiling for gross margins across the business?